Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study.
Diem L, Daponte A, Findling O, Miclea A, Briner M, Salmen A, Gold R, Kilidireas C, Chan A, Evangelopoulos ME, Hoepner R. Diem L, et al. Among authors: kilidireas c. Neurol Neuroimmunol Neuroinflamm. 2020 Jan 14;7(2):e660. doi: 10.1212/NXI.0000000000000660. Print 2020 Mar. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 31937596 Free PMC article.
Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course.
Zoehner G, Miclea A, Salmen A, Kamber N, Diem L, Friedli C, Bagnoud M, Ahmadi F, Briner M, Sédille-Mostafaie N, Kilidireas C, Stefanis L, Chan A, Hoepner R, Evangelopoulos ME. Zoehner G, et al. Among authors: kilidireas c. Ther Adv Neurol Disord. 2019 Sep 27;12:1756286419878340. doi: 10.1177/1756286419878340. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 31632461 Free PMC article.
IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients.
Vakrakou AG, Tzanetakos D, Evangelopoulos ME, Fragoulis GE, Kazakou P, Lekka E, Kafasi N, Tzartos JS, Andreadou E, Koutsis G, Gialafos E, Dimitrakopoulos A, Zampeli E, Rontogianni D, Theocharis S, Zapanti E, Stathopoulos PA, Anagnostouli M, Stefanis L, Kilidireas C. Vakrakou AG, et al. Among authors: kilidireas c. J Neuroimmunol. 2021 Dec 15;361:577759. doi: 10.1016/j.jneuroim.2021.577759. Epub 2021 Oct 29. J Neuroimmunol. 2021. PMID: 34742035
The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.
Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Kilidireas C, Voumvourakis K. Tsivgoulis G, et al. Among authors: kilidireas c. PLoS One. 2015 Mar 10;10(3):e0116511. doi: 10.1371/journal.pone.0116511. eCollection 2015. PLoS One. 2015. PMID: 25756363 Free PMC article. Review.
The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.
Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Papathanasopoulos P, Kilidireas C, Voumvourakis K, Dardiotis E; HELANI (Hellenic Academy of Neuroimmunology). Tsivgoulis G, et al. Among authors: kilidireas c. PLoS One. 2015 Dec 7;10(12):e0144538. doi: 10.1371/journal.pone.0144538. eCollection 2015. PLoS One. 2015. PMID: 26642051 Free PMC article. Review.
Specific myeloid signatures in peripheral blood differentiate active and rare clinical phenotypes of multiple sclerosis.
Vakrakou AG, Paschalidis N, Pavlos E, Giannouli C, Karathanasis D, Tsipota X, Velonakis G, Stadelmann-Nessler C, Evangelopoulos ME, Stefanis L, Kilidireas C. Vakrakou AG, et al. Among authors: kilidireas c. Front Immunol. 2023 Jan 25;14:1071623. doi: 10.3389/fimmu.2023.1071623. eCollection 2023. Front Immunol. 2023. PMID: 36761741 Free PMC article.
Comment on: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".
Tsivgoulis G, Palaiodimou L, Katsanos AH, Voumvourakis K, Hadjigeorgiou GM, Heliopoulos I, Karapanayiotides T, Papathanasopoulos P, Kilidireas C, Grigoriadis N. Tsivgoulis G, et al. Among authors: kilidireas c. CNS Drugs. 2019 Mar;33(3):293-295. doi: 10.1007/s40263-019-00615-5. CNS Drugs. 2019. PMID: 30806966 No abstract available.
Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.
Vakrakou AG, Tzanetakos D, Evangelopoulos ME, Argyrakos T, Tzartos JS, Anagnostouli M, Andreadou E, Koutsis G, Velonakis G, Toulas P, Gialafos E, Dimitrakopoulos A, Psimenou E, Stefanis L, Kilidireas C. Vakrakou AG, et al. Among authors: kilidireas c. Ther Adv Neurol Disord. 2021 May 18;14:17562864211006503. doi: 10.1177/17562864211006503. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34046086 Free PMC article.
Co-occurrence between hereditary angioedema and multiple sclerosis: Therapeutic management of both diseases with fingolimod.
Vakrakou AG, Tzanetakos D, Giagkou E, Evangelopoulos ME, Anagnostouli M, Andreadou E, Koutsis G, Dimitrakopoulos A, Gialafos E, Tzartos JS, Kompoti E, Fragoulis GE, Stefanis L, Kilidireas C. Vakrakou AG, et al. Among authors: kilidireas c. Clin Neurol Neurosurg. 2022 May;216:107222. doi: 10.1016/j.clineuro.2022.107222. Epub 2022 Mar 28. Clin Neurol Neurosurg. 2022. PMID: 35378480
Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece.
Dardiotis E, Perpati G, Borsos M, Nikolaidis I, Tzanetakos D, Deretzi G, Koutlas E, Kilidireas C, Mitsikostas DD, Hadjigeorgiou G, Grigoriadis N; AURELIO investigators. Dardiotis E, et al. Among authors: kilidireas c. Neurol Ther. 2022 Sep;11(3):1375-1390. doi: 10.1007/s40120-022-00384-2. Epub 2022 Jul 13. Neurol Ther. 2022. PMID: 35829919 Free PMC article.
53 results